MabVax Therapeutics Holdings, Inc. discovers new drugs with a focus on cancer treatments. We use proprietary Target-Related Affinity Profiling (TRAP) technology to identify potential drug compounds and advance therapies for patients worldwide.
Advancing therapies for cancer and blood disorders
Chemotherapy-Resistant Tumors
Our lead drug candidate targets chemotherapy-resistant tumors and is undergoing clinical trials for ovarian cancer, non-small cell lung cancer, and other solid tumors. Telcyta is designed to improve outcomes for patients who have limited treatment options.
Blood Disorders
Candidate for neutropenia and myelodysplastic syndrome (MDS). Potential treatment to address unmet needs in hematologic conditions.
View Details →Target-Related Affinity Profiling
Proprietary technology that identifies potential drug compounds by analyzing how they interact with proteins.
View Details →Early-Stage Compounds
A portfolio of anticancer compounds in preclinical and early development stages, driven by TRAP-based discovery.
View Details →Protein Interaction
Ongoing research into new targets and mechanisms to expand our therapeutic pipeline.
View Details →Telik discovers new drugs, focusing mainly on treatments for cancer. The company uses its proprietary Target-Related Affinity Profiling (TRAP) technology to identify potential drug compounds by analyzing the way they interact with proteins.
Lead drug candidate Telcyta targets chemotherapy-resistant tumors and is undergoing clinical trials for several kinds of cancer, including ovarian and non-small cell lung cancers. Another candidate, Telintra, may treat blood disorders, including neutropenia and myelodysplastic syndrome. Telik has a host of other anticancer compounds at earlier stages of development.
Proprietary Target-Related Affinity Profiling for drug discovery
Targeting chemotherapy-resistant tumors in clinical trials
Potential treatment for blood disorders
Anticancer compounds in development
Dedicated to advancing cancer therapeutics and drug discovery
CEO
Executive leader with 20+ years in biotech and pharmaceuticals, focused on bringing novel therapies to patients.
Chief Scientific Officer
Drives discovery and TRAP technology development. Expert in protein-drug interactions and medicinal chemistry.
VP Clinical Development
Leads clinical strategy for Telcyta and Telintra. Extensive experience in oncology and hematology trials.
Head of Research
Oversees preclinical research and pipeline expansion. Focus on anticancer compounds and novel targets.
MabVax Therapeutics is building a team committed to advancing cancer therapeutics and improving patient outcomes. We seek scientists, clinicians, and professionals who share our mission to discover and develop novel drugs.
We offer competitive compensation, comprehensive benefits, and the opportunity to work on meaningful therapies from discovery through clinical development at our San Diego headquarters.
Stay connected with our latest announcements
Updates on our lead candidate Telcyta in Phase II/III trials for ovarian cancer and chemotherapy-resistant tumors. Patient enrollment and trial sites advancing.
Read More →Our Target-Related Affinity Profiling platform was featured at the American Association for Cancer Research annual meeting, highlighting novel drug discovery applications.
Read More →MabVax Therapeutics announces a collaboration to advance Telintra for blood disorders including neutropenia and myelodysplastic syndrome.
Read More →For investor inquiries, partnership opportunities, or general questions
11535 Sorrento Valley Rd Ste 400
San Diego, California 92121-1309
United States